Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus warfarin in thrombotic antiphospholipid syndrome
2012-002345-38Phase 2Completed
- Sponsor
- University College London
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in antiphospholipid syndrome (APS) comparing Rivaroxaban with Warfarin (2 arms). Primary endpoint: Percentage change in endogenous thrombin potential. Started Oct 2012; status: completed.
02
Drugs
rivaroxabanwarfarin
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on 2012-002345-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002345-38.